157 related articles for article (PubMed ID: 35512501)
1. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva L; Estruch BC; Merino JAG; Meca-Lallana V; Río J; Rodríguez-Antigüedad A; Agüera E; Ara JR; Luque AA; Garcia CA; Blanco Y; Castillo-Triviño T; Costa-Frossard L; González Platas M; Pascual LL; Llaneza-González M; Ginés MLM; Matías-Guiu J; Meca-Lallana JE; Bilbao MM; Sempere AP; Romero-Pinel L; Saiz A; Moral E
Mult Scler Relat Disord; 2022 Jul; 63():103805. PubMed ID: 35512501
[TBL] [Abstract][Full Text] [Related]
2. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
[TBL] [Abstract][Full Text] [Related]
3. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.
Meca-Lallana JE; Martínez Yélamos S; Eichau S; Llaneza MÁ; Martín Martínez J; Peña Martínez J; Meca Lallana V; Alonso Torres AM; Moral Torres E; Río J; Calles C; Ares Luque A; Ramió-Torrentà L; Marzo Sola ME; Prieto JM; Martínez Ginés ML; Arroyo R; Otano Martínez MÁ; Brieva Ruiz L; Gómez Gutiérrez M; Rodríguez-Antigüedad Zarranz A; Sánchez-Seco VG; Costa-Frossard L; Hernández Pérez MÁ; Landete Pascual L; González Platas M; Oreja-Guevara C
Neurologia (Engl Ed); 2024 Mar; 39(2):196-208. PubMed ID: 38237804
[TBL] [Abstract][Full Text] [Related]
4. Modified Delphi study of decision-making around treatment sequencing in relapsing-remitting multiple sclerosis.
Piena MA; Schoeman O; Palace J; Duddy M; Harty GT; Wong SL
Eur J Neurol; 2020 Aug; 27(8):1530-1536. PubMed ID: 32302441
[TBL] [Abstract][Full Text] [Related]
5. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero S; Lebrun-Frénay C; Reyes S; Amato MP; Campins M; Farez M; Filippi M; Hacohen Y; Hemmer B; Juuti R; Magyari M; Oreja-Guevara C; Siva A; Vukusic S; Tintoré M
Eur J Neurol; 2023 Aug; 30(8):2144-2176. PubMed ID: 37293849
[TBL] [Abstract][Full Text] [Related]
6. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
Brownlee WJ; Wolf C; Hartung HP; Dingermann T; Anshasi N; Clark RA; Trojano M; Selmaj K; Uitdehaag BM; Tur C; Wuerfel J; Dallmann G; Witte J; Sintzel M; Bobrovnikova O; Cohen JA
Mult Scler; 2022 Dec; 28(14):2177-2189. PubMed ID: 36000489
[TBL] [Abstract][Full Text] [Related]
7. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.
Miller RM; Happe LE; Meyer KL; Spear RJ
J Manag Care Pharm; 2012; 18(1):54-62. PubMed ID: 22235955
[TBL] [Abstract][Full Text] [Related]
8. Criteria for Critical Care Infants and Children: PICU Admission, Discharge, and Triage Practice Statement and Levels of Care Guidance.
Frankel LR; Hsu BS; Yeh TS; Simone S; Agus MSD; Arca MJ; Coss-Bu JA; Fallat ME; Foland J; Gadepalli S; Gayle MO; Harmon LA; Hill V; Joseph CA; Kessel AD; Kissoon N; Moss M; Mysore MR; Papo ME; Rajzer-Wakeham KL; Rice TB; Rosenberg DL; Wakeham MK; Conway EE;
Pediatr Crit Care Med; 2019 Sep; 20(9):847-887. PubMed ID: 31483379
[TBL] [Abstract][Full Text] [Related]
9. How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Bigaut K; Cohen M; Durand-Dubief F; Maillart E; Planque E; Zephir H; Lebrun-Frenay C; de Seze J;
Mult Scler Relat Disord; 2021 Aug; 53():103076. PubMed ID: 34161898
[TBL] [Abstract][Full Text] [Related]
10. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
García Merino A; Ramón Ara Callizo J; Fernández Fernández O; Landete Pascual L; Moral Torres E; Rodríguez-Antigüedad Zarrantz A
Neurologia; 2017 Mar; 32(2):113-119. PubMed ID: 27157522
[TBL] [Abstract][Full Text] [Related]
11. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
12. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
De Sèze J; Suchet L; Mekies C; Manchon E; Labauge P; Guennoc AM; Defer G; Clavelou P; Castelnovo G; Bourre B; Bensa-Koscher C; Al Khedr A; Le Mao J; Villemur L; Bouée S; Luciani L; Vermersch P
Neurol Ther; 2023 Apr; 12(2):351-369. PubMed ID: 36564664
[TBL] [Abstract][Full Text] [Related]
13. A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands.
Michels RE; Peters ML; Schiffers KM; Bouma PA; Hengstman GI; van Munster CE; Zeinstra E; Voer G; Krol M
J Comp Eff Res; 2021 Feb; 10(2):93-100. PubMed ID: 33275036
[No Abstract] [Full Text] [Related]
14. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.
Hoffmann-Vold AM; Maher TM; Philpot EE; Ashrafzadeh A; Barake R; Barsotti S; Bruni C; Carducci P; Carreira PE; Castellví I; Del Galdo F; Distler JHW; Foeldvari I; Fraticelli P; George PM; Griffiths B; Guillén-Del-Castillo A; Hamid AM; Horváth R; Hughes M; Kreuter M; Moazedi-Fuerst F; Olas J; Paul S; Rotondo C; Rubio-Rivas M; Seferian A; Tomčík M; Uzunhan Y; Walker UA; Więsik-Szewczyk E; Distler O
Lancet Rheumatol; 2020 Feb; 2(2):e71-e83. PubMed ID: 38263663
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations.
Skromne-Eisenberg E; Treviño-Frenk I; Llamosa García Velázquez GL; Quiñones-Aguilar S; Rivas-Alonso V; Maza-Flores M; Macías-Islas MÁ; Llamas-López L; González-Amezquita V; León-Jiménez C; Medina-López Z; Ortiz-Maldonado JF; Santos-Diaz MA; Bertado-Cortés B; Flores-Rivera JJ; Ordóñez-Boschetti L
Mult Scler Relat Disord; 2021 Aug; 53():103053. PubMed ID: 34139461
[TBL] [Abstract][Full Text] [Related]
16. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
Riva A; Barcella V; Benatti SV; Capobianco M; Capra R; Cinque P; Comi G; Fasolo MM; Franzetti F; Galli M; Gerevini S; Meroni L; Origoni M; Prosperini L; Puoti M; Scarpazza C; Tortorella C; Zaffaroni M; Moiola L
Mult Scler; 2021 Mar; 27(3):347-359. PubMed ID: 32940128
[TBL] [Abstract][Full Text] [Related]
17. Expert opinion on the use of contraception in people with multiple sclerosis.
Hillert J; Bove R; Haddad LB; Hellwig K; Houtchens M; Magyari M; Merki-Feld GS; Montgomery S; Nappi RE; Stenager E; Thompson H; Tulek Z; Verdun Di Cantogno E; Simoni M
Mult Scler; 2024 Mar; ():13524585241228103. PubMed ID: 38456514
[TBL] [Abstract][Full Text] [Related]
18. Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group.
Averbeck MA; Iacovelli V; Panicker J; Schurch B; Finazzi Agrò E
Neurourol Urodyn; 2020 Jan; 39(1):73-82. PubMed ID: 31746485
[TBL] [Abstract][Full Text] [Related]
19. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
Moiola L; Barcella V; Benatti S; Capobianco M; Capra R; Cinque P; Comi G; Fasolo MM; Franzetti F; Galli M; Gerevini S; Meroni L; Origoni M; Prosperini L; Puoti M; Scarpazza C; Tortorella C; Zaffaroni M; Riva A
Mult Scler; 2021 Mar; 27(3):331-346. PubMed ID: 32940121
[TBL] [Abstract][Full Text] [Related]
20. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
Braune S; Rossnagel F; Dikow H; Bergmann A;
BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
